Private equity firm JLL Partners has agreed to acquire BioClinica (NASDAQ: BIOC) for approximately $123 million. Concurrently, JLL has also agreed to acquire CoreLab Partners, an Ampersand Capital Partners portfolio company, and will merge the two entities. BioClinica provides clinical trial management solutions for pharmaceutical, biotechnology and medical device companies and other organizations. CoreLab provides medical imaging solutions and cardiac safety services to the global biopharmaceutical industry. The combined company, which will be led by current BioClinica president and CEO Mark L. Weinstein, will provide medical imaging services and eClinical solutions for clinical trials. Ampersand Capital, which is providing an equity commitment alongside JLL to help finance the BioClinica purchase, will be a significant investor in the combined company.